Fresenius is showing early signs of recovery, with improved profitability and a simplified structure, making it a promising investment despite past delays. The company’s divestments and deleveraging ...
Fresenius Medical Care is a BBB-rated leader in kidney care with a 3.1% yield, undervalued at 14x P/E, and poised for growth by 2025-2026E. Despite recent earnings declines, the company expects growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback